These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 19344292)

  • 1. Generic and therapeutic statin switches and disruptions in therapy.
    Chapman RH; Benner JS; Girase P; Benigno M; Axelsen K; Liu LZ; Nichol MB
    Curr Med Res Opin; 2009 May; 25(5):1247-60. PubMed ID: 19344292
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Compliance after switching from branded to generic statins.
    Romanelli RJ; Jukes T; Segal JB
    Pharmacoepidemiol Drug Saf; 2014 Oct; 23(10):1093-100. PubMed ID: 24817435
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictors of statin compliance after switching from branded to generic agents among managed-care beneficiaries.
    Romanelli RJ; Segal JB
    J Gen Intern Med; 2014 Oct; 29(10):1372-8. PubMed ID: 24957381
    [TBL] [Abstract][Full Text] [Related]  

  • 4. LDL-C goal attainment in patients who remain on atorvastatin or switch to equivalent or non-equivalent doses of simvastatin: a retrospective matched cohort study in clinical practice.
    Rublee DA; Burke JP
    Postgrad Med; 2010 Mar; 122(2):16-24. PubMed ID: 20203452
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of Switching From High-Efficacy Lipid-Lowering Therapies to Generic Simvastatin on LDL-C Levels and LDL-C Goal Attainment Among High-Risk Primary and Secondary Prevention Populations in the United Kingdom.
    Cao X; Ejzykowicz F; Ramey DR; Sajjan S; Ambegaonkar BM; Mavros P; Tunceli K
    Clin Ther; 2015 Apr; 37(4):804-15. PubMed ID: 25626487
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of low-density lipoprotein cholesterol reduction after switching patients on other statins to rosuvastatin or simvastatin in a real-world clinical practice setting.
    Fox KM; Gandhi SK; Ohsfeldt RL; Davidson MH
    Am J Manag Care; 2007 Dec; 13 Suppl 10():S270-5. PubMed ID: 18095777
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of out-of-pocket expenses on discontinuation of statin therapy: a cohort study in Finland.
    Helin-Salmivaara A; Korhonen MJ; Alanen T; Huupponen R
    J Clin Pharm Ther; 2012 Feb; 37(1):58-64. PubMed ID: 21410736
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patient co-payment and adherence to statins: a review and case studies.
    Simoens S; Sinnaeve PR
    Cardiovasc Drugs Ther; 2014 Feb; 28(1):99-109. PubMed ID: 24150747
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of generic switching on concerns about medicine and non-persistence among Danish adults in a general practice setting.
    Rathe JØ
    Dan Med J; 2015 Oct; 62(10):B5148. PubMed ID: 26441397
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Does a single-pill antihypertensive/lipid-lowering regimen improve adherence in US managed care enrolees? A non-randomized, observational, retrospective study.
    Hussein MA; Chapman RH; Benner JS; Tang SS; Solomon HA; Joyce A; Foody JM
    Am J Cardiovasc Drugs; 2010; 10(3):193-202. PubMed ID: 20387911
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of generic substitution on refill adherence to statin therapy: a nationwide population-based study.
    Trusell H; Sundell KA
    BMC Health Serv Res; 2014 Dec; 14():626. PubMed ID: 25475416
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic dose assessment of patient switching from atorvastatin to simvastatin.
    Hess G; Sanders KN; Hill J; Liu LZ
    Am J Manag Care; 2007 Jun; 13 Suppl 3():S80-5. PubMed ID: 17596116
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical consequences of generic substitution of lamotrigine for patients with epilepsy.
    LeLorier J; Duh MS; Paradis PE; Lefebvre P; Weiner J; Manjunath R; Sheehy O
    Neurology; 2008 May; 70(22 Pt 2):2179-86. PubMed ID: 18505997
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiovascular event rates in atorvastatin patients versus patients switching from atorvastatin to simvastatin.
    Jacobson TA; Wertz DA; Kuznik A; Cziraky M
    Curr Med Res Opin; 2013 Jul; 29(7):773-81. PubMed ID: 23647370
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Moving from A to Z: successful implementation of a statin switch program by a large physician group.
    Sy FZ; Choe HM; Kennedy DM; Standiford CJ; Parsons DM; Bruhnsen KD; Stevenson JG; Bernstein SJ
    Am J Manag Care; 2009 Apr; 15(4):233-40. PubMed ID: 19355796
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lowering copayments: impact of simvastatin patent expiration on patient adherence.
    Sedjo RL; Cox ER
    Am J Manag Care; 2008 Dec; 14(12):813-8. PubMed ID: 19067498
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The need for a systematic approach to statin switching: an analysis of real-world experience.
    Kakavas PW; McManus JL; Wolfe TA; Guidry T; Flores DN; Ter Riet LB; Glover JJ; Sell H
    J Cardiovasc Nurs; 2013; 28(6):565-72. PubMed ID: 23064180
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical and economic outcomes in patients switched to simvastatin in a community-based family medicine practice.
    Willey VJ; Reinhold JA; Willey KH; Kelly BL; Cziraky MJ
    Int J Clin Pract; 2010 Aug; 64(9):1235-8. PubMed ID: 20653799
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Persistence of atorvastatin and simvastatin among patients with and without prior cardiovascular diseases: a US managed care study.
    Foody JM; Joyce AT; Rudolph AE; Liu LZ; Benner JS
    Curr Med Res Opin; 2008 Jul; 24(7):1987-2000. PubMed ID: 18554430
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of Prescription Drug Coupons on Statin Utilization and Expenditures: A Retrospective Cohort Study.
    Daubresse M; Andersen M; Riggs KR; Alexander GC
    Pharmacotherapy; 2017 Jan; 37(1):12-24. PubMed ID: 27455456
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.